Antivirals reduce influenza viral replication and illness measures, particularly if initiated early, within 48 h of symptom onset. Whether experimental antivirals that reduce respiratory syncytial virus (RSV) load would also reduce disease is unknown. This study compares viral and disease dynamics in humans experimentally infected with influenza or RSV.
Methods
Clinical strains of RSV-A and influenza A were inoculated intranasally into 20 and 17 healthy volunteers, respectively, on day 0. Symptom scores and nasal washes were performed twice daily, and daily mucus weights were collected. Viral loads in nasal washes were quantified by culture (plaque assay in HEp-2 cells for RSV and by end point dilution in Madin–Darby canine kidney cells for influenza).
Results
After influenza inoculation, influenza viral load and illness markers increased simultaneously until day 2. Within individual subjects, peak influenza load occurred 0.4 days (95% CI -0.4, 1.3) before peak symptoms. Influenza viral load and disease declined thereafter. After RSV inoculation, a longer incubation period occurred prior to viral detection and symptom onset. RSV load and disease increased together until day 5. Within individual subjects, peak RSV loads occurred 0.2 days (95% CI -0.7, 1.05) before peak symptoms, after which both illness measures and viral load declined together.
Conclusions
Viral and disease dynamics in experimental human infections suggest that reducing RSV load, if timed similarly to clinically-effective influenza antivirals, might be expected to have a similar or greater window of opportunity for reducing clinical RSV disease.
References
1.
FalseyA.R., HennesseyP.A., FormicaM.A., CoxC., WalshE.E.Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med2005; 352: 1749–1759.
2.
HanL.L., AlexanderJ.P., AndersonL.J.Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis1999; 179: 25–30.
3.
NicholsonK.G.Impact of influenza and respiratory syncytial virus on mortality in England and Wales from January 1975 to December 1990. Epidemiol Infect1996; 116: 51–63.
4.
ThompsonW.W., ShayD.K., WeintraubE.Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA2003; 289: 179–186.
5.
ZambonM.C., StocktonJ.D., ClewleyJ.P., FlemingD.M.Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet2001; 358: 1410–1416.
6.
GlezenW.P., TaberL.H., FrankA.L., KaselJ.A.Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child1986; 140: 543–546.
7.
MontoA.S., SullivanK.M.Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect1993; 110: 145–160.
8.
ShayD.K., HolmanR.C., NewmanR.D.Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA1999; 282: 1440–1446.
American Academy of Pediatrics Committee on Infectious Diseases.Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics1996; 97: 137–140.
KimpenJ.L., SchaadU.B.Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J1997; 16: 479–481.
13.
American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics2003; 112: 1442–1446.
14.
DeVincenzoJ.P.RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J2008; 27Suppl 1: S118–S122.
15.
HaydenF.G.Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther2012; 17Suppl 1: 133–141.
16.
HaydenF.G., MontoA.S.Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother1986; 29: 339–341.
17.
ZlydnikovD.M., KubarO.I., KovalevaT.P., KamforinL.E.Study of rimantadine in the USSR: a review of the literature. Rev Infect Dis1981; 3: 408–421.
18.
HaydenF.G., OsterhausA.D., TreanorJ.J.Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med1997; 337: 874–880.
19.
TreanorJ.J., HaydenF.G., VroomanP.S.Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA2000; 283: 1016–1024.
20.
WhitleyR.J., HaydenF.G., ReisingerK.S.Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J2001; 20: 127–133.
21.
DeVincenzoJ., Lambkin-WilliamsR., WilkinsonT.A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A2010; 107: 8800–8805.
22.
DeVincenzoJ P.. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir Ther2012; 17: 213–225.
23.
ZamoraM.R., BudevM., RolfeM.RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med2011; 183: 531–538.
24.
GlanvilleA., MuskM., ZamoraM.Results of a Phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients.RSV Symposium. 27–30 September 2012, Santa Fe, NM, USA.
25.
HirstG.K.The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med1942; 75: 49–64.
26.
FriesL., LambkinR., GelderC.FluINsure, an inactivated trivalent influenza vaccine for intranasal administration, is protective in human challenge with A/Panama/2007/99 (H3N2) virus. Int Congr Ser2004; 1263: 661–665.
27.
DeVincenzoJ.P., WilkinsonT., VaishnawA.Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med2010; 182: 1305–1314.
28.
ZaasA.K., ChenM., VarkeyJ.Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe2009; 6: 207–217.
29.
DevincenzoJ P.. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res2004; 56: 914–917.
30.
MeguroH., BryantJ.D., TorrenceA.E., WrightP.F.Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol1979; 9: 175–179.
31.
ReedL.J., MuenchH.A simple method of estimating fifty percent endpoints. Am J Hyg1938; 27: 493–497.
32.
AndriesK., MoeremansM., GeversT.Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res2003; 60: 209–219.
33.
BonfantiJ.F., DoubletF., FortinJ.Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. J Med Chem2007; 50: 4572–4584.
34.
ChapmanJ., AbbottE., AlberD.G.RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother2007; 51: 3346–3353.
35.
CianciC., MeanwellN., KrystalM.Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. J Antimicrob Chemother2005; 55: 289–292.
36.
DouglasJ.L.In search of a small-molecule inhibitor for respiratory syncytial virus. Expert Rev Anti Infect Ther2004; 2: 625–639.
MasonS.W., LawetzC., GaudetteY.Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res2004; 32: 4758–4767.
41.
SudoK., MiyazakiY., KojimaN.YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Antiviral Res2005; 65: 125–131.
42.
WydeP.R., LaquerreS., ChettyS.N.Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res2005; 68: 18–26.
43.
LeekhaS., ZitterkopfN.L., EspyM.J.Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol2007; 28: 1071–1076.
44.
NicholsonK.G., AokiF.Y., OsterhausA.D.Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet2000; 355: 1845–1850.
45.
AokiF.Y., MacleodM.D., PaggiaroP.Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother2003; 51: 123–129.
46.
HaydenF.G., TreanorJ.J., FritzR.S.Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA1999; 282: 1240–1246.
47.
MosconaA.Neuraminidase inhibitors for influenza. N Engl J Med2005; 353: 1363–1373.
48.
CarratF., VerguE., FergusonN.M.Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol2008; 167: 775–785.
49.
LauL.L., CowlingB.J., FangV.J.Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis2010; 201: 1509–1516.
50.
BuckinghamS.C., JafriH.S., BushA.J.A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis2002; 185: 1222–1228.
51.
DeVincenzoJ.P., AitkenJ.B., HarrisonL.G.Opportunities for early therapy of respiratory syncytial virus (RSV) infection: what happens before hospitalization. Antiviral Res2004; 62: 47–51.
